NVCR

NovoCure Limited Ordinary Shares

13.04

USD

NVCR Earnings Reports

Positive Surprise Ratio

NVCR beat 24 of 41 last estimates.

59%

Next Report

Date of Next Report

Apr 20, 2026

Estimate for Q1 26 (Revenue/ EPS)

$171.22M

-$0.49

Implied change from Q4 25 (Revenue/ EPS)

-1.79%

+122.73%

Implied change from Q1 25 (Revenue/ EPS)

+10.47%

+58.06%

NovoCure Limited Ordinary Shares earnings per share and revenue

On Feb 26, 2026, NVCR reported earnings of -0.22 USD per share (EPS) for Q4 25, beating the estimate of -0.41 USD, resulting in a 47.58% surprise. Revenue reached 174.35 million, compared to an expected 176.82 million, with a -1.40% difference. The market reacted with a -3.74% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 171.22 million USD, implying an increase of 122.73% EPS, and decrease of -1.79% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

EyePoint, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.76

Actual

-$0.81

Surprise

-6.20%

Kura Oncology, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.62

Actual

-$0.92

Surprise

-47.84%

CorMedix Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.83

Actual

$0.61

Surprise

-26.73%

REGENXBIO Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.97

Actual

-$1.30

Surprise

-33.31%

Lexicon Pharmaceuticals, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.07

Actual

-$0.04

Surprise

+43.18%

Contineum Therapeutics, Inc. Class A Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.49

Surprise

-18.41%

Lineage Cell Therapeutics, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.05

Actual

$0.00

Surprise

+100.00%

Atea Pharmaceuticals, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.56

Surprise

-5.44%

Liquidia Corporation Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.18

Actual

$0.15

Surprise

-18.48%

Aligos Therapeutics, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$1.88

Actual

-$1.91

Surprise

-1.11%

FAQ

What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.22, beating estimates by 47.58%, and revenue of $174.35M, -1.4% below expectations.

How did the market react to NovoCure Limited Ordinary Shares's Q4 2025 earnings?

The stock price moved down -3.74%, changed from $14.18 before the earnings release to $13.65 the day after.

When is NovoCure Limited Ordinary Shares expected to report next?

The next earning report is scheduled for Apr 20, 2026.

What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?

Based on 7 analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.49 and revenue of $171.22M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.